X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs VENUS REMEDIES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS VENUS REMEDIES IPCA LABS/
VENUS REMEDIES
 
P/E (TTM) x 39.2 -862.0 - View Chart
P/BV x 3.0 0.3 1,192.1% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   VENUS REMEDIES
EQUITY SHARE DATA
    IPCA LABS
Mar-17
VENUS REMEDIES
Mar-16
IPCA LABS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs643218 295.0%   
Low Rs50382 612.4%   
Sales per share (Unadj.) Rs254.4365.6 69.6%  
Earnings per share (Unadj.) Rs16.11.5 1,081.4%  
Cash flow per share (Unadj.) Rs29.837.9 78.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.6382.5 50.9%  
Shares outstanding (eoy) m126.2011.44 1,103.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.4 548.7%   
Avg P/E ratio x35.7101.0 35.3%  
P/CF ratio (eoy) x19.24.0 486.3%  
Price / Book Value ratio x2.90.4 750.7%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3001,717 4,211.9%   
No. of employees `00013.31.0 1,304.2%   
Total wages/salary Rs m6,960324 2,145.4%   
Avg. sales/employee Rs Th2,413.54,100.7 58.9%   
Avg. wages/employee Rs Th523.2318.0 164.5%   
Avg. net profit/employee Rs Th152.416.7 914.7%   
INCOME DATA
Net Sales Rs m32,1064,183 767.6%  
Other income Rs m22620 1,122.9%   
Total revenues Rs m32,3324,203 769.3%   
Gross profit Rs m4,448812 548.0%  
Depreciation Rs m1,730417 414.9%   
Interest Rs m241380 63.4%   
Profit before tax Rs m2,70335 7,701.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m67518 3,730.4%   
Profit after tax Rs m2,02817 11,929.4%  
Gross profit margin %13.919.4 71.4%  
Effective tax rate %25.051.6 48.4%   
Net profit margin %6.30.4 1,554.1%  
BALANCE SHEET DATA
Current assets Rs m17,3402,771 625.8%   
Current liabilities Rs m9,5591,931 494.9%   
Net working cap to sales %24.220.1 120.8%  
Current ratio x1.81.4 126.4%  
Inventory Days Days100125 80.2%  
Debtors Days Days5754 105.8%  
Net fixed assets Rs m20,7795,328 390.0%   
Share capital Rs m252114 220.6%   
"Free" reserves Rs m24,4994,177 586.5%   
Net worth Rs m24,5534,376 561.0%   
Long term debt Rs m3,5171,911 184.1%   
Total assets Rs m39,5958,428 469.8%  
Interest coverage x12.21.1 1,119.2%   
Debt to equity ratio x0.10.4 32.8%  
Sales to assets ratio x0.80.5 163.4%   
Return on assets %5.74.7 121.7%  
Return on equity %8.30.4 2,126.3%  
Return on capital %10.56.6 158.9%  
Exports to sales %48.60-   
Imports to sales %14.220.5 69.4%   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571858 532.5%   
Fx inflow Rs m15,6170-   
Fx outflow Rs m5,828858 679.0%   
Net fx Rs m9,790-858 -1,140.6%   
CASH FLOW
From Operations Rs m2,764469 589.6%  
From Investments Rs m-1,43229 -4,903.1%  
From Financial Activity Rs m-1,591-464 343.3%  
Net Cashflow Rs m-25935 -750.1%  

Share Holding

Indian Promoters % 45.9 32.9 139.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.2 6,333.3%  
FIIs % 25.3 0.6 4,362.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 66.4 26.2%  
Shareholders   36,892 20,121 183.4%  
Pledged promoter(s) holding % 2.1 36.4 5.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jan 18, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - FULFORD INDIA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS